Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes

被引：14
|
作者：
Zweck, Elric [1 ]
Westenfeld, Ralf [1 ]
Szendroedi, Julia [2 ]
机构：
[1] Heinrich Heine Univ, Dusseldorf, Germany
[2] German Diabet Ctr, Dusseldorf, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2019年 / 381卷 / 21期
关键词：
GLP-1 RECEPTOR AGONISTS;
D O I：
10.1056/NEJMc1913157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2075 / 2076
页数：2
相关论文
共 50 条
  • [1] Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Husain, Mansoor
    Birkenfeld, Andreas L.
    Donsmark, Morten
    Dungan, Kathleen
    Eliaschewitz, Freddy G.
    Franco, Denise R.
    Jeppesen, Ole K.
    Lingvay, Ildiko
    Mosenzon, Ofri
    Pedersen, Sue D.
    Tack, Cees J.
    Thomsen, Mette
    Vilsboll, Tina
    Warren, Mark L.
    Bain, Stephen C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (09): : 841 - 851
  • [2] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes reply
    Husain, Mansoor
    Donsmark, Morten
    Bain, Stephen C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2076 - 2077
  • [3] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Cosmi, Franco
    Latini, Roberto
    Nicolucci, Antonio
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 890 - 890
  • [4] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso, Steven P.
    Bain, Stephen C.
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    Jodar, Esteban
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Rosenstock, Julio
    Seufert, Jochen
    Warren, Mark L.
    Woo, Vincent
    Hansen, Oluf
    Holst, Anders G.
    Pettersson, Jonas
    Vilsboll, Tina
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1834 - 1844
  • [5] Oral semaglutide in type 2 diabetes
    Anderson, Sarah L.
    Beutel, Trevor R.
    Trujillo, Jennifer M.
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (04)
  • [6] Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
    Doggrell, Sheila A.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (05) : 489 - 492
  • [7] Type-2 Diabetes: Examination of cardiovascular Risk Profile of oral Semaglutide
    Lichert, Frank
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2019, 14 (06)
  • [8] Oral semaglutide for the treatment of type 2 diabetes
    Hedrington, Maka S.
    Davis, Stephen N.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (02) : 133 - 141
  • [9] Oral Semaglutide (Rybelsus) for Type 2 Diabetes
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1583): : 166 - 168
  • [10] Type-2 Diabetes: Examination of cardiovascular Risk Profile of oral Semaglutide Comment
    Ritzel, Robert
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2019, 14 (06) : 436 - 437
12345